Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04795635 · ClinicalTrials.gov registry record · NA

Axon Therapy for Post-Traumatic Peripheral Neuropathic Pain Compared to Conventional Medical Management

A NA study of Neuropathic Pain and Peripheral Neuropathy, sponsored by NeuraLace Medical.

Active
Registry status
NA
Development phase
61
Enrollment target
3
Study locations

NCT04795635 is a NA study of Neuropathic Pain and Peripheral Neuropathy that is active but no longer recruiting, run by NeuraLace Medical. The registered enrollment target is 61 participants, below the 99-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (38% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04795635, a NA study of Neuropathic Pain and Peripheral Neuropathy, is active but no longer recruiting, sponsored by NeuraLace Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
61 participants
Enrollment target
3
Study locations

Study Summary

Compare Axon Therapy using transcutaneous magnetic stimulation (tMS) against conventional medical management in treating post-traumatic peripheral neuropathic pain (PTPNP).

Interventions

  • DEVICE CMM + Axon Therapy

Study Locations (3)

New Jersey

  • National Spine and Pain Centers - Shrewsbury

North Carolina

  • Carolinas Pain Institute - Winston-Salem

South Carolina

  • SC Pain and Spine Specialists (Crescent Moon Research Corp) - Murrells Inlet

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2021-04-14
Est. Completion 2024-08-22
Phase NA

Sponsor

NeuraLace Medical

3 total trials

What the Registry Record Tells You About NCT04795635

The ClinicalTrials.gov registry entry for NCT04795635 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (38% lower). The listed sponsor is NeuraLace Medical, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Neuropathic Pain appearing as the primary indexed condition, and to 1 intervention - of which CMM + Axon Therapy is the first listed.

NCT04795635 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New Jersey, North Carolina, South Carolina.

Frequently Asked Questions

What is clinical trial NCT04795635 about?

NCT04795635 is a clinical study titled "Axon Therapy for Post-Traumatic Peripheral Neuropathic Pain Compared to Conventional Medical Management". Compare Axon Therapy using transcutaneous magnetic stimulation (tMS) against conventional medical management in treating post-traumatic peripheral neuropathic pain (PTPNP).

What is the current status of trial NCT04795635?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 61 participants. The study started on 2021-04-14. Estimated completion is 2024-08-22.

What conditions does trial NCT04795635 study?

This clinical trial studies the following conditions: Neuropathic Pain, Peripheral Neuropathy.

What interventions are being tested in trial NCT04795635?

The interventions under investigation include: CMM + Axon Therapy (DEVICE).

Who is sponsoring clinical trial NCT04795635?

This trial is sponsored by NeuraLace Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04795635 being conducted?

This trial has 3 study locations across New Jersey, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neuropathic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.